Complete Report @ http://goo.gl/xccdVj "Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015" report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the world’s leading life science companies.

1. Global Co-development Deals in Pharma, Biotech & Diagnostics 2010 -
2015
By
Current Partnering
Browse more reports on Life Sciences @
www.rnrmarketresearch.com/reports/life-sciences .
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
Single User License: US $2995
Corporate User License: US $14995
Published: April 2015

2. The Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 report
provides comprehensive understanding and unprecedented access to the co-development
deals and agreements entered into by the world’s leading life science companies.
The report provides a detailed understand and analysis of how and why companies enter co-
development deals.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical
insight into the negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are triggered and rights transferred
– contract documents provide this insight where press releases and databases do not.
Complete report available @ http://www.rnrmarketresearch.com/co-development-terms-
and-agreements-in-pharma-biotech-and-diagnostics-market-report.html .
Global Co-development Deals in Pharma, Biotech &
Diagnostics 2010 - 2015
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441

3. This report contains links to online copies of actual co-development contract documents as
submitted to the Securities Exchange Commission by biopharma companies and their
partners.
Contract documents provide the answers to numerous questions about a prospective
partner’s flexibility on a wide range of important issues, many of which will have a significant
impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of co-development dealmaking and
business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides
an analysis of the trends in co-development as well as a discussion on the merits of the type
of deal.
Purchase a copy of this report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=201950 .
Global Co-development Deals in Pharma, Biotech &
Diagnostics 2010 - 2015
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441

4. Chapter 3 provides an overview of the structure of co-development deals. The chapter
includes numerous case studies to enable understanding of both pure co-development deals
and multicomponent deals where co-development forms a part.
Chapter 4 provides a review of the leading co-development deals since 2010. Deals are listed
by headline value, signed by big pharma and big biotech, most active big pharma, and most
active of all biopharma companies. Where the deal has an agreement contract published at
the SEC a link provides online access to the contract via the Current Agreements deals and
alliances database.
Chapters 5 and 6 provide a comprehensive listing of the top 50 bigpharma and bigbiotech
companies with a brief summary followed by a comprehensive listing of co-development
contract deals available in the public domain. Where available, each deal title links via
Current Agreements deals and alliances database to an online version of the actual contract
document, providing easy access to each contract document on demand.
Inquire for discount @
http://www.rnrmarketresearch.com/contacts/discount?rname=201950 .
Global Co-development Deals in Pharma, Biotech &
Diagnostics 2010 - 2015
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441

5. The report also includes numerous table and figures that illustrate the trends and activities in
co- development dealmaking since 2010.
In addition, a comprehensive appendix is provided organized by co-development partnering
company A-Z, stage of development, therapeutic target, and technology type and deal type
definitions. Each deal title links via Web link to an online version of the deal record and where
available, the contract document, providing easy access to each contract document on
demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about
co-development partnering in the research, development and commercialization of
technologies and products.
Report scope
Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 is intended to
provide the reader with an in-depth understanding of the co-development trends and
structure of deals entered into by leading life science companies worldwide.
Global Co-development Deals in Pharma, Biotech &
Diagnostics 2010 - 2015
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441

6. Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 includes:
• Trends in co-development dealmaking in the biopharma industry since 2010
• Analysis of co-development deal structure
• Case studies of real-life co-development deals
• Comprehensive listing of co-development deals since 2010
• Access to co-development contract documents
• Key financial benchmarks for headline, upfront, milestone and royalty rates
• The leading co-development deals by value since 2010
• Most active co-development dealmakers since 2010
• The leading co-development partnering resources
In Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 available
deals and contracts are listed by:
• Company A-Z
• Headline value
• Therapeutic area
• Technology type
Global Co-development Deals in Pharma, Biotech &
Diagnostics 2010 - 2015
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441

7. Each deal title links via Web link to an online version of the actual deal record and where
available, contract document, providing easy access to each contract document on demand.
The Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 report
provides comprehensive access to available contract documents for co-development deals.
Analyzing actual contract agreements allows assessment of the following:
• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How do milestone align with clinical stage development phases?
• How are sales and payments audited?
• What is the deal term?
Global Co-development Deals in Pharma, Biotech &
Diagnostics 2010 - 2015
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441

8. Continued:
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal
type?
• Which jurisdiction does the company insist upon for agreement law?
Inquire before buying this report @
http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=201950 .
Global Co-development Deals in Pharma, Biotech &
Diagnostics 2010 - 2015
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441

9. Benefits
• Global Co-development Deals in Pharma, Biotech & Diagnostics 2010-2015 provides the
reader with the following key benefits:
• In-depth understanding of co-development deal trends since 2010
• Analysis of the structure of co-development agreements with numerous real life case
studies
• Comprehensive listing of all co-development deals since 2010, together with deal terms,
value and press release
• Comprehensive access to actual co-development contracts entered into by the world’s life
science companies
• Analysis of key deal financials including headline value, upfront, milestone payments and
royalty rates
• Insight into the terms included in a co-development agreement, together with real world
clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner
companies
Global Co-development Deals in Pharma, Biotech &
Diagnostics 2010 - 2015
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441

10. For more details contact Mr. Ritesh Tiwari: sales@rnrmarketresearch.com / +18883915441
© RnRMarketResearch.com ; sales@rnrmarketresearch.com ;
+1 888 391 5441
RnR Market Research
RnRMarketResearch.com, an online repository of market research reports, offers in-depth
analysis of over 5000 market segments. RnR Market Research library has syndicated reports by
leading market research publishers across the globe.
Global Co-development Deals in Pharma, Biotech &
Diagnostics 2010 - 2015